Who are RTXM83's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DURVALUMAB, AVELUMAB, Avelumab first-line maintenance, PD-1 / PD-L1 monoclonal antibody, Adebrelimab combined with SOX regimen, Pf-06865571.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rtxm83.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RTXM83 — Competitive Intelligence Brief

RTXM83 (RTXM83) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-L1 Oncology Biologic Live · refreshed every 30 min

Target snapshot

RTXM83 (RTXM83) — mAbxience Research S.L.. RTXM83 is a monoclonal antibody targeting PD-L1.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RTXM83 TARGET	RTXM83	mAbxience Research S.L.	phase 3	PD-1/PD-L1 inhibitor	PD-L1
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
AstraZeneca · 2 drugs in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
EMD Serono · 1 drug in this class
EMS · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
Cellvax Therapeutics Inc · 1 drug in this class
Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RTXM83 — Competitive Intelligence Brief. https://druglandscape.com/ci/rtxm83. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab